# DESCRIPTION

## STATEMENT REGARDING FEDERAL FUNDING

- disclose government funding

## BACKGROUND

### 1. Technical Field

- introduce TRegS expansion

### 2. Background Information

- discuss IL-2 and TRegS

## SUMMARY

- introduce IL-2Rα/IL-2Rβ/γc complex
- describe IL-2 responsiveness
- introduce single-chain immunocytokines
- describe immunocytokine structure
- discuss immunocytokine binding
- introduce methods for making immunocytokines
- describe immunocytokine administration
- discuss treatment of autoimmune diseases
- discuss treatment of transplant rejection
- introduce nucleic acids encoding immunocytokines
- describe methods for treating autoimmune diseases
- describe methods for stimulating TRegS

## DETAILED DESCRIPTION

- introduce single-chain immunocytokines
- describe structure of single-chain immunocytokines
- provide methods for making single-chain immunocytokines
- describe administration of single-chain immunocytokines
- define single-chain immunocytokines as fusion proteins
- describe cytokine fusion to antibody or fragment
- provide examples of single-chain immunocytokines
- describe binding of single-chain immunocytokines to IL-2Rα/IL-2Rβ/γc polypeptide complex
- describe immunoglobulin heavy chain structure and function
- provide exemplary immunoglobulin heavy chain sequences
- define single-chain immunocytokine
- describe IL-2 polypeptide
- specify IL-2 polypeptide sequence
- describe immunoglobulin light chain
- specify immunoglobulin light chain sequence
- describe signal sequence
- provide exemplary immunoglobulin light chain
- describe modifications to immunoglobulin light chain
- describe fusion of IL-2 polypeptide and immunoglobulin light chain
- specify linker sequence
- describe modifications to linker
- describe immunoglobulin light chains
- specify components of immunoglobulin light chains
- describe modifications to immunoglobulin light chains
- describe stability of single-chain immunocytokines
- describe methods for determining stability
- describe binding affinity of single-chain immunocytokines
- describe methods for determining binding affinity
- describe activation of Effs by single-chain immunocytokines
- describe methods for making single-chain immunocytokines
- describe nucleic acid vectors for encoding polypeptides
- describe assembly of polypeptides into single-chain immunocytokines
- define purified polypeptide or nucleic acid
- describe purification methods
- introduce methods and materials for treating autoimmune disease
- describe treating mammals with autoimmune disease
- list examples of autoimmune diseases
- describe identifying mammals with autoimmune disease
- introduce treating transplant rejection
- describe treating mammals with transplant rejection
- list examples of transplantable organs and tissues
- describe identifying mammals with transplant rejection
- describe administering single-chain immunocytokines
- describe using single-chain immunocytokines in combination therapy
- describe formulating single-chain immunocytokines into compositions
- describe administering compositions
- describe effective doses of single-chain immunocytokines
- describe frequency of administration
- describe duration of treatment
- describe monitoring autoimmune disease
- introduce alternative uses of methods and materials

## EXAMPLES

- describe engineered cytokine/antibody fusion
- demonstrate proper assembly and binding of immunocytokine
- show selective bias of immunocytokine toward TReg cells
- optimize expression and function of immunocytokine
- demonstrate improved molecular bias of optimized immunocytokines
- show activity of immunocytokine on human PBMCs
- summarize results of immunocytokine experiments
- discuss other embodiments of the invention

### EXAMPLE 1

- introduce engineered cytokine/antibody fusion
- describe benefits of targeted cytokine therapy

### EXAMPLE 2

- demonstrate proper assembly and binding of immunocytokine

### EXAMPLE 3

- show selective bias of immunocytokine toward TReg cells

### EXAMPLE 4

- optimize expression and function of immunocytokine
- demonstrate improved molecular bias of optimized immunocytokines
- show activity of immunocytokine on human PBMCs
- summarize results of optimized immunocytokine experiments

## OTHER EMBODIMENTS

- discuss other embodiments of the invention

